Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/73576
Title: MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)
Authors: Ortega, Vanesa
Lao, Jarunan
Garau, I.
Afonso, N.
Calvo, Lourdes
Fernández, Y.
Martinez-Garcia, M.
Blanco, E.
Zamora, Pilar
García García, Margarita Inmaculada 
Illarramendi, J. J.
Rodríguez, C.
Aguirre, E.
Pérez, J.
Castan, J. Cortes
Llombart-Cussac, Antonio
UNESCO Clasification: 320101 Oncología
Issue Date: 2016
Journal: Annals of Oncology 
Abstract: Background: Eribulin improved overall survival (OS) in ≥3 line treatment of MBC pts. In a large retrospective study, short disease-free interval (DFI) and prior taxane therapy have been associated with worse OS in pts receiving first-line chemotherapy for HER2[-] MBC. The aim of MERIBEL trial is to evaluate the efficacy and safety of eribulin as first-line therapy for HER2[-] MBC pts with these poor prognostic factors. Methods: Phase II, multicenter, single arm, trial. Eribulin (1.23 mg/m2) as single-agent was administered on days 1 and 8 of 21 day cycles until progression or unacceptable toxicity. Principal selection criteria: (1) HER2[-] pts without prior chemotherapy for MBC; (2) prior taxane therapy (≥4 cycles) for early BC; (3) less than 36 months* (mo) between the last taxane cycle and relapse; (4) RECIST v1.1 evaluable disease; (5) no symptomatic brain involvement. (*) Amendment to 48 mo. Primary outcome was time to progression (TTP). Secondary endpoints included OS, progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR) and toxicity. We included 53 women from 61 pts recruited between SEP/2013 to MAR/2015 across 12 sites and 2 countries. Results: Median age 51 years [range 23-83]; 50.9% were ECOG 0; 45.3% were triple-negative; 84.9% received prior anthracyclines. Median DFI was 15.7 mo [0.1-46.5]; and 52.8% had visceral metastases (11.3% with ≥3 involved organ sites). Median follow-up was 12.7 mo [0.2 – 30.5]. Median TTP was 4.1 mo [95%CI 2.2-6], median PFS was 4.3 mo [2.2-6.5], and median OS has not been reached yet. The 1-year TTP, PFS and OS rates were 16.2%, 24.3%, and 65.9%, respectively. The ORR was 20.8% and CBR, 26.4%. Eribulin all grades and 3/4 adverse events (AEs) were reported in 96.2% and 71.7% of the pts, respectively. The most common grade 3/4 AEs were neutropenia (28.3%), leukopenia (17%), peripheral neuropathy (5.7%) and asthenia (5.7%). One patient experienced febrile neutropenia. Percentages of pts with AEs leading to treatment discontinuation, reduction, or delay were 15.1%, 9.4%, and 26.4%, respectively. Conclusions: Eribulin is effective and safe as first-line therapy for aggressive taxane-resistant HER2[-] MBC pts.
URI: http://hdl.handle.net/10553/73576
ISSN: 0923-7534
DOI: 10.1093/annonc/mdw365.17
Source: Annals of Oncology [ISSN 0923-7534], v. 27, (Octubre 2016)
Appears in Collections:Artículos
Show full item record

Page view(s)

47
checked on Feb 17, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.